Pharmafile Logo
Pharmafocus logo
Advanced Search

Imfinzi

Showing 10 posts of 25 posts found.

astrazeneca-sign

AstraZeneca’s Imfinzi meets endpoint at Phase 3 interim analysis in extensive-stage small cell lung cancer

June 27, 2019
Research and Development AstraZeneca, Imfinzi, pharma

AstraZeneca has lifted the curtain on new Phase 3 data for Imfinzi (durvalumab) in the first-line treatment of extensive-stage small …

News

AstraZeneca’s Imfinzi to be made available via Cancer Drugs Fund in England

March 28, 2019
Sales and Marketing AstraZeneca, Cancer, Imfinzi, NHS, NICE, UK, lung cancer

AstraZeneca’s PD-L1 inhibitor Imfinzi (durvalumab) will now be made available to English lung cancer patients on the NHS via the …

News
astrazeneca_sign_sky

AstraZeneca’s Imfinzi immunotherapy combo fails to show benefit in lung cancer

November 16, 2018
Medical Communications, Research and Development AstraZeneca, Cancer, Imfinzi, lung cancer, pharma

AstraZeneca has revealed that its immunotherapy combo of Imfinzi (durvalumab) and tremelimumab failed to meet its primary endpoint in a …

News
astrazeneca-sign

AstraZeneca chalks up double Japanese approval in lung and breast cancer

July 2, 2018
Sales and Marketing AstraZeneca, Cancer, Imfinzi, NSCLD, breast cancer, lung cancer, lynparza, pharma

It’s a big step forward for AstraZeneca’s global marketing operations as the company announced that two of its products have …

News
astrazeneca_sign_sky

AstraZeneca’s Imfinzi becomes India’s first available immunotherapy for lung cancer

June 22, 2018
Medical Communications, Sales and Marketing AstraZeneca, Imfinzi, India, NSCLC, lung cancer, pharma

In a big step forward for India as AstraZeneca announces that its checkpoint inhibitor Imfinzi (durvalumab) has secured approval in …

News

AZ’s Imfinzi hits second major milestone at Phase 3 in unresectable lung cancer

May 25, 2018
Medical Communications, Research and Development AstraZeneca, Imfinzi, NSCLC, lung cancer, pharma

AstraZeneca and its global biologics R&D MedImmune have lifted the curtain on new Phase 3 data for their immunotherapy Imfinzi …

News
astrazeneca_logo_building

AZ’s combo woes continue, with failure in lung cancer

April 24, 2018
Manufacturing and Production, Research and Development AstraZeneca, Imfinzi, biotech, drugs, pharma, pharmaceutical

AstraZeneca has been hit by a fresh blow in its search for an immunotherapy combination treatment that could differentiate it …

News
fda_building_web

Adaxis-AZ immunotherapy combo hit by clinical hold after death

March 13, 2018
Manufacturing and Production, Research and Development Adaxis, AstraZeneca, Imfinzi, biotech, drugs, immunotherapy, pharma, pharmaceutical

Adaxis and AstraZeneca announced that they had agreed a combination program for axalimogene filolisbac and Imfinzi, respectively, back in 2014 …

News
astrazeneca_sign_sky

AZ’s Imfinzi seals blockbuster lung cancer market with FDA nod

February 19, 2018
Sales and Marketing AstraZeneca, Imfinzi, biotech, drugs, pharma, pharmaceutical

AstraZeneca’s immunotherapy, Imfinzi, arrived to the industry as a failure – there were big hopes resting on the company’s Mystic …

News
astrazeneca_building_white

AZ’s Imfinzi scores FDA breakthrough therapy designation in wake of major trial failure

July 31, 2017
Sales and Marketing AstraZeneca, Imfinzi, drugs, healthcare, mystic, phaarmaceutical, pharma

Still reeling from the public reaction to the flop of its key Mystic trial, where its injectable immunotherapy drug Imfinzi …

News

Latest content

GSK shares data from global shingles survey

December 1, 2023

AbbVie to acquire ImmunoGen for approximately $10.1bn

December 1, 2023

FDA accepts NDA for Karuna’s schizophrenia treatment

November 30, 2023

Vivos Therapeutics gains FDA 510(k) clearance for sleep apnea treatment device

November 30, 2023

Tolremo doses first patient in phase 1 trial for drug to combat transcriptional cancer drug resistance

November 29, 2023